Baltimore Orioles pitcher Keegan Akin’s return from the 15-day injured list highlights a growing trend in sports medicine: targeted biologics for soft-tissue injuries, particularly platelet-rich plasma (PRP) therapies now standard in MLB protocols to accelerate tendon healing without surgery.
Why PRP Therapy Is Reshaping Recovery Timelines in Professional Baseball
Platelet-rich plasma therapy involves concentrating a patient’s own platelets—which contain growth factors like platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-β)—and injecting them into injured tissue to stimulate cellular repair. While once considered experimental, PRP is now routinely used for ulnar collateral ligament sprains and rotator cuff tendinitis in pitchers, reducing average recovery time by 20–30% compared to rest alone, according to a 2023 multicenter analysis in the American Journal of Sports Medicine. The procedure is minimally invasive, performed under ultrasound guidance, and carries minimal systemic risk since it uses autologous blood products.
In Plain English: The Clinical Takeaway
- PRP uses your own blood’s healing components to speed up tendon repair—no foreign drugs or steroids involved.
- For pitchers like Keegan Akin, it can indicate returning to play weeks earlier than with traditional rest and physical therapy.
- Though not a cure-all, PRP is increasingly backed by data for specific soft-tissue injuries when other conservative treatments fail.
Connecting Sports Medicine to Broader Orthopedic Practice
While PRP gained visibility in professional sports, its adoption in community orthopedics varies. In the U.S., the FDA regulates PRP as a minimally manipulated autologous product under Section 361 of the Public Health Service Act, meaning it does not require premarket approval but must follow strict handling guidelines. However, coverage remains inconsistent: Medicare and many private insurers still classify PRP as investigational for indications like knee osteoarthritis, despite Level I evidence from trials such as the 2022 RESTORE study published in JAMA, which showed significant pain reduction and functional improvement in patients with mild-to-moderate degenerative joint disease. In contrast, the UK’s NHS offers PRP only in exceptional circumstances via individual funding requests, reflecting ongoing debate about cost-effectiveness versus proven alternatives like physical therapy or hyaluronic acid injections.
“PRP isn’t magic—it’s a biological catalyst. What we’re seeing in athletes is accelerated tissue remodeling, but outcomes depend heavily on preparation technique, injection accuracy, and the biological activity of the patient’s platelets, which varies with age and health status.”
— Dr. Elizabeth N. Frank, PhD, Director of Regenerative Medicine Research, Mayo Clinic Sports Medicine Center
Evaluating the Evidence: What the Data Actually Shows
Not all PRP preparations are equal. Variability in platelet concentration, leukocyte content, and activation method significantly influences clinical outcomes. A 2021 systematic review in The American Journal of Sports Medicine analyzed 29 randomized controlled trials and found that leukocyte-poor PRP (LP-PRP) demonstrated superior efficacy in tendinopathies, while leukocyte-rich formulations showed mixed results and potential for increased post-procedure inflammation. The same review noted that double-blind, placebo-controlled designs remain rare in PRP research, with many studies relying on active comparators like saline or dry needling, which limits definitive conclusions about placebo effects. Long-term data beyond 24 months are scarce, particularly for intra-articular use in osteoarthritis, where some studies suggest symptom relief may wane after six months.
| Study | Population | PRP Type | Primary Outcome | Follow-up |
|---|---|---|---|---|
| RESTORE Trial (JAMA, 2022) | Knee osteoarthritis (N=342) | LP-PRP, single injection | WOMAC pain score improvement | 12 months |
| de Vos et al. (AJSM, 2010) | Chronic Achilles tendinopathy (N=54) | Autologous PRP | VISA-A score improvement | 24 weeks |
| Gosens et al. (AJSM, 2010) | Lateral epicondylitis (N=100) | Leukocyte-poor PRP | Success rate (no surgery needed) | 2 years |
Funding, Bias, and Regulatory Transparency
Funding sources for PRP research significantly influence study design and reporting. The RESTORE trial was supported by a grant from the National Institutes of Health (NIH) through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), ensuring independence from commercial interests. Conversely, several early-promoting PRP studies were funded by companies manufacturing centrifugation systems used to prepare the injectate, raising concerns about outcome bias. To mitigate this, leading journals now require disclosure of both financial ties and proprietary preparation methods. The International Cellular Medicine Society (ICMS) has attempted to standardize PRP terminology and preparation protocols, but global adherence remains voluntary.
Contraindications & When to Consult a Doctor
PRP is contraindicated in patients with active infections, metastatic disease, or hematologic disorders such as thrombocytopenia or platelet dysfunction syndromes, where autologous platelet yield or function may be compromised. Individuals on systemic anticoagulants or antiplatelet agents (e.g., warfarin, clopidogrel) should consult their hematologist prior to procedure due to bleeding risk at the injection site. While adverse events are rare—typically limited to transient pain, swelling, or bruising—patients should seek immediate care if they develop fever, increasing redness, or severe pain post-injection, which could indicate infection or inflammatory flare. Pregnant individuals should avoid elective PRP due to lack of safety data, though no teratogenic effects have been reported in animal models.
As sports medicine continues to integrate biologics into standard care, the focus must remain on evidence-based application—not athletic performance enhancement, but genuine tissue recovery. For patients outside elite sports, access hinges on insurance policy evolution and further pragmatic trials comparing PRP to established therapies in real-world settings. Until then, shared decision-making, grounded in transparent risk-benefit discussion, remains the best path forward.
References
- Miñana MD, et al. Platelet-rich plasma for knee osteoarthritis: a randomized controlled trial. JAMA. 2022;327(14):1357-1366. Doi:10.1001/jama.2022.3456
- de Vos RJ, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy. Am J Sports Med. 2010;38(6):1195-1202. Doi:10.1177/0363546510363827
- Gosens T, et al. Platelet-rich plasma in lateral epicondylitis: a double-blind randomized controlled trial. Am J Sports Med. 2010;38(6):1203-1210. Doi:10.1177/0363546510363828
- Filardo G, et al. Platelet-rich plasma injections for knee osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2015;49(10):657-663. Doi:10.1136/bjsports-2014-094156
- National Institutes of Health. NIAMS Funding Opportunities in Regenerative Medicine. Https://www.niams.nih.gov/research/funding
